It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Consulting or Advisory Role: Novartis, Pfizer, Merck, Lilly, AstraZeneca, Genentech, Eisai, Sanofi, Bristol Myers Squibb, Seagen, Daiichi Sankyo, Immunomedics/Gilead Sciences, Inc., Zymeworks, ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a ...